External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Clinical trial NCT04697446 · UNKNOWN

Trial details

NCT number: NCT04697446
Sponsor: Blueprint Medicines Corporation
Status: UNKNOWN
Study type: OBSERVATIONAL

RET-fusion Non Small Cell Lung Cancer Lung Neoplasm Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Diseases Head and Neck Neoplasms

Start date: 2020-12-01
Primary completion: 2021-10-31
Enrollment: 279

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.